Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity

Cell Mol Gastroenterol Hepatol. 2019;7(3):623-639. doi: 10.1016/j.jcmgh.2018.12.009. Epub 2019 Jan 7.

Abstract

Background & aims: Chemokine-mediated immune cell recruitment plays pivotal roles in liver inflammation. C-C motif chemokine ligand 5 (CCL5) has been shown to be responsible for the recruitment of monocytes/macrophages and has been implicated in various liver diseases, including nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. Previous studies have also shown that inhibition of CCL5 appears to be a promising therapeutic approach for several chronic liver diseases. However, whether blocking CCL5 could benefit immune cell-mediated hepatitis remains largely elusive.

Methods: By adopting a specific agonist, alpha-galactosylceramide (α-Galcer), of invariant natural killer T cells (iNKTs), we investigated the function and mechanism of CCL5 in the iNKT induced murine hepatitis model.

Results: We found significantly increased CCL5 expression in α-Galcer-induced hepatitis murine model. Such an increase in CCL5 is mainly enriched in non-parenchymal cells such as macrophages and iNKTs but not in hepatocytes. Surprisingly, CCL5 blockage by genetic deletion of Ccl5 does not affect the α-Galcer-induced iNKT activation but greatly worsens α-Galcer-induced liver injury accompanied by an increased hepatic neutrophil infiltration. Mechanistically, we demonstrated that greater neutrophil accumulation in the liver is responsible for the enhanced liver injury in Ccl5-/- mice. Such an increased hepatic neutrophil infiltration is mainly caused by an enhanced CXCL1-CXCR2 signal in Ccl5-/- mice. Therapeutically, either antibody-mediated neutrophil depletion or a CXCR2 antagonist, SB225002, mediated CXCR2 signaling blockage significantly ameliorated α-Galcer-induced liver injury in Ccl5-/- mice.

Conclusions: Our present study demonstrates that (1) α-Galcer-induced murine hepatitis could greatly induce CCL5 production in macrophages and iNKT cells; (2) loss of CCL5 could enhance CXCL1 expression in hepatocytes and activate CXCL1-CXCR2 axis in neutrophils to augment their hepatic infiltration; and (3) neutrophil depletion or blockage of CXCL1-CXCR2 axis greatly improves α-Galcer-induced liver injury in Ccl5-/- mice. This study suggests that clinical utilization of CCL5 blockage may compensatorily induce the activation of other chemokine pathways to enhance neutrophil recruitment and liver injury in hepatitis.

Keywords: CCL5; CXCL1; CXCR2; Invariant NKT; Neutrophils.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Chemokine CCL5 / deficiency*
  • Chemokine CCL5 / metabolism
  • Chemokine CXCL1 / genetics
  • Chemokine CXCL1 / metabolism
  • Cytokines / biosynthesis
  • Disease Models, Animal
  • Galactosylceramides / administration & dosage
  • Gene Deletion*
  • Hepatitis / blood
  • Hepatitis / immunology*
  • Hepatitis / pathology
  • Hepatocytes / metabolism
  • Hepatocytes / pathology
  • Humans
  • Liver / injuries
  • Liver / metabolism
  • Liver / pathology
  • Lymphocyte Activation / immunology
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Natural Killer T-Cells / immunology*
  • Neutrophil Infiltration
  • Neutrophils / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptors, Interleukin-8B / genetics*
  • Receptors, Interleukin-8B / metabolism
  • Spleen / metabolism
  • Up-Regulation*
  • Young Adult

Substances

  • Chemokine CCL5
  • Chemokine CXCL1
  • Cytokines
  • Galactosylceramides
  • RNA, Messenger
  • Receptors, Interleukin-8B
  • alpha-galactosylceramide